AstraZeneca PLC

AZN

GB0009895292

Pharmaceuticals

Real-time Estimate Cboe Europe Other stock markets 10:43:36 16/07/2024 BST			5-day change	1st Jan Change
12,044 ^GBX	-0.50%		+0.99%	+13.79%

07-15	Global markets live: Airbus, Burberry, AT&T, Boeing, Vinfast...
07-15	AstraZeneca: acquisition of Amolyt Pharma finalized	CF

ASTRAZENECA : Gets a Neutral rating from Credit Suisse

January 06, 2023 at 02:27 pm

In a research note, Credit Suisse analyst Dominic Lunn has maintained his recommendation on the stock with a Neutral rating. The target price is increased from GBX 11000 to GBX 11800.

Latest news about AstraZeneca PLC

Global markets live: Airbus, Burberry, AT&T, Boeing, Vinfast...	07-15
AstraZeneca: acquisition of Amolyt Pharma finalized	07-15	CF
AstraZeneca Closes $1.05 Billion Amolyt Pharma Acquisition	07-15	MT
AstraZeneca PLC completed the acquisition of Amolyt Pharma SAS for $1.05 billion.	07-14	CI
Instil Bio Shares Surge Following Rental Agreement with AstraZeneca	07-12	DJ
Sector Update: Health Care Stocks Mixed Premarket Friday	07-12	MT
Instil Bio Signs Lease With AstraZeneca Pharmaceuticals at California Facility; Shares Rise After Hours	07-11	MT
ASTRAZENECA : Deutsche Bank reiterates its Neutral rating	07-10	ZD
Barclays raises Kerry, cuts Hunting, Wood Group	07-10	AN
ASTRAZENECA : JP Morgan reaffirms its Buy rating	07-10	ZD
AstraZeneca's Tagrisso Approved by EU as First-Line Treatment for Non-Small Cell Lung Cancer	07-05	MT
AstraZeneca: cancer treatment approved by the EU	07-05	CF
AstraZeneca drug Tagrisso gets EU approval for cancer form	07-05	AN
EU Approves AstraZeneca's Tagrisso Combo as Non-small Cell Lung Cancer Treatment	07-05	MT
ASTRAZENECA : Goldman Sachs maintains a Buy rating	07-04	ZD
ASTRAZENECA : Buy rating from Berenberg	07-03	ZD
Aptamer shares jump as inks agreement with AstraZeneca	07-03	AN
Aptamer Group plc Announces New Agreement with AstraZeneca to Evaluate the Optimer Fibrotic Liver Delivery Vehicles for the Targeted Delivery of SiRNA	07-03	CI
ASTRAZENECA : Jefferies reaffirms its Neutral rating	07-02	ZD
Deutsche Bank cuts Quilter, ups Polar Capital	07-02	AN
European Equities Close Higher in Monday Trading; Eurozone Manufacturing Contraction Widens in June	07-01	MT
UK Stocks Flat; Manufacturing Sector Remains in Expansion Zone	07-01	MT
AstraZeneca's Potential Covid-19 Prevention Drug Gets EU Accelerated Assessment	07-01	MT
AstraZeneca's Imfinzi, Lynparza Combination Recommended for Approval in Europe as Endometrial Cancer Treatment	07-01	MT
AstraZeneca applies to the EMA for a Covid antibody	07-01	CF

AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (4.4%). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).

Sector

Pharmaceuticals

Calendar

25/07/2024 - Q2 2024 Earnings Release

Related indices

STOXX EUROPE 600 (EUR) , FTSE 100

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

ASTRAZENECA : Strong Q1 raises hopes of a guidance upgrade

April 25, 2024 at 05:02 pm

More Strategies

Ratings for AstraZeneca PLC

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

157.2 USD

Average target price

177.6 USD

Spread / Average Target

+13.00%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ASTRAZENECA PLC	+13.79%	244B
ELI LILLY AND COMPANY	+63.05%	856B
NOVO NORDISK A/S	+38.96%	631B
JOHNSON & JOHNSON	-4.78%	359B
MERCK & CO., INC.	+17.52%	325B
ABBVIE INC.	+8.43%	297B
ROCHE HOLDING AG	+4.95%	234B
NOVARTIS AG	+16.28%	226B
AMGEN INC.	+14.63%	177B
PFIZER, INC.	+1.08%	165B

Other Pharmaceuticals

AstraZeneca PLC

Equities

AZN

GB0009895292

Pharmaceuticals

ASTRAZENECA : Gets a Neutral rating from Credit Suisse

Latest news about AstraZeneca PLC

Chart AstraZeneca PLC

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for AstraZeneca PLC

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals